BioNTech adds bispecific candidate ... including one candidate that hits PD-L1 and TGFβ and another that inhibits TIGIT and ...

BioNTech said that its VEGF bispecific sets it apart from competitors because of its mechanism and how it plans to ...

BioNTech is acquiring Chinese biotech Biotheus for $800 million upfront plus $150 million in milestones, gaining multiple ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

Data, including overall survival, from ARC-10, a randomized study evaluating domvanalimab plus zimberelimab in front-line, PD-L1-high ... for the Fc-silent anti-TIGIT antibody domvanalimab ...

The company’s most advanced asset is dom, an Fc-silent anti-TIGIT monoclonal antibody that ... being investigated for the treatment of all PD-L1 subgroups of 1L NSCLC. The Phase 3 trial (STAR ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

The drugmakers will explore the efficacy of Dato-DXd in combination with other drugs in PD-L1-expressing or EGFR-mutated NSCLC in these studies.

TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 ...

This study is a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody ... or non-squamous NSCLC with a PD-L1 tumor proportion score of ...